Navigation Links
AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
Date:5/10/2011

REDWOOD CITY, Calif., May 10, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX) ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that the opposition period for a patent granted by the European Patent Office expired on April 21 and to date there is no indication that the patent has been opposed. The patent (European patent EP2114383), covers small-volume NanoTab® dosage forms for transmucosal administration containing the opioid sufentanil. This patent covers elements of AcelRx's dispensing technology and also provides patent protection of specific pharmacokinetic parameters derived from sublingual administration using the NanoTab technology. AcelRx has exclusive rights to the patent, which covers key aspects of AcelRx's product candidates ARX-01, ARX-02 and ARX-03.  AcelRx registered the European patent in England, Germany, France, Spain, Italy, Switzerland / Lichtenstein, Denmark, Netherlands, Portugal, and Sweden.

AcelRx developed the NanoTab technology as a basis for delivering sufentanil, a highly lipophilic, high therapeutic index opioid, to control acute and breakthrough pain. The NanoTab provides for rapid uptake of the drug via sublingual tissues, enabling a rapid and consistent onset of effect.  

"This patent is the first to issue from our broad portfolio of pending intellectual property which provides long-term market exclusivity for AcelRx NanoTab technology and pipeline product candidates through at least 2027 in key markets" commented Richard King, AcelRx President and Chief Executive Officer. Mr. King added, "This patent is an important component of AcelRx's formidable intellectual property portfolio covering our sufentanil product candidates.  We see this patent issuance as a key milestone that underscores the durable commercial potential of our market-focused acute and breakthrough pain products."  

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is entering Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02, which is designed to offer rapid onset of analgesia, appropriate offset of pain relief and mitigation of opioid abuse and misuse for the treatment of breakthrough pain experienced by cancer patients, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' intellectual property, breadth and commercial potential of its patent portfolio, market for its products, its clinical trials and product candidate development. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceutical's product development activities and clinical trials; its ability to obtain and maintain intellectual property protection for its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approval of its product candidates; its plans to research, develop and commercialize its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' Securities and Exchange Commission filings and reports, including its Annual Report on Form 10-K for the year ended December 31, 2010. AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
2. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
3. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
4. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
5. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
8. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
9. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
10. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
11. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
Breaking Medicine News(10 mins):